124 related articles for article (PubMed ID: 16506366)
1. Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan.
Chang CY; Huang SP; Chiu HM; Lee YC; Chen MF; Lin JT
Hepatogastroenterology; 2006; 53(67):1-4. PubMed ID: 16506366
[TBL] [Abstract][Full Text] [Related]
2. [Diagnostic usefulness of Ca 19-9 antigen in cancer of the pancreas and neoplasms of the pancreato-biliary intersection].
Robles-Diáz G; Aceves G; Galván E
Gac Med Mex; 1990; 126(2):78-82; discussion 82-3. PubMed ID: 2387490
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic value of serum CA 19-9 determination in digestive tract cancer].
Chen SB
Zhonghua Zhong Liu Za Zhi; 1990 Jan; 12(1):58-60. PubMed ID: 2364873
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
5. [Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer?].
Mery CM; Duarte-Rojo A; Paz-Pineda F; Gómez E; Robles-Díaz G
Rev Invest Clin; 2001; 53(6):511-7. PubMed ID: 11921523
[TBL] [Abstract][Full Text] [Related]
6. [Clinical evaluation of serum TAC-41 in various digestive cancers].
Sato S; Yamanaka T; Kimura K
Rinsho Byori; 1989 Nov; 37(11):1259-62. PubMed ID: 2601083
[TBL] [Abstract][Full Text] [Related]
7. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.
Kang CM; Kim JY; Choi GH; Kim KS; Choi JS; Lee WJ; Kim BR
J Surg Res; 2007 Jun; 140(1):31-5. PubMed ID: 17418869
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic role of serum interleukin 6 and CA 19-9 in patients with cholangiocarcinoma.
Tangkijvanich P; Thong-ngam D; Theamboonlers A; Hanvivatvong O; Kullavanijaya P; Poovorawan Y
Hepatogastroenterology; 2004; 51(55):15-9. PubMed ID: 15011822
[TBL] [Abstract][Full Text] [Related]
9. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
10. [Is the carbohydrate antigen Ca 19.9 useful in the diagnosis of pancreatic carcinoma?].
Santander C; Jiménez I; Martín E; Melón A; Pajares JM
Rev Esp Enferm Dig; 1994 Nov; 86(5):819-21. PubMed ID: 7848693
[TBL] [Abstract][Full Text] [Related]
11. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population.
Kim JE; Lee KT; Lee JK; Paik SW; Rhee JC; Choi KW
J Gastroenterol Hepatol; 2004 Feb; 19(2):182-6. PubMed ID: 14731128
[TBL] [Abstract][Full Text] [Related]
12. [Clinical investigation of carbohydrate antigen CA-50].
Ishii M; Abe O; Okura H; Okazaki N; Kawai T; Saito Y; Sawabu N; Takamizawa Y; Takeuchi T; Niitani H
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2548-55. PubMed ID: 3304170
[TBL] [Abstract][Full Text] [Related]
13. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
Kumar Y; Tapuria N; Kirmani N; Davidson BR
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
[TBL] [Abstract][Full Text] [Related]
14. How useful are clinical, biochemical, and cross-sectional imaging features in predicting potentially malignant or malignant cystic lesions of the pancreas? Results from a single institution experience with 220 surgically treated patients.
Goh BK; Tan YM; Thng CH; Cheow PC; Chung YF; Chow PK; Wong WK; Ooi LL
J Am Coll Surg; 2008 Jan; 206(1):17-27. PubMed ID: 18155564
[TBL] [Abstract][Full Text] [Related]
15. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection.
Bloomston M; Bekaii-Saab TS; Kosuri K; Cowgill SM; Melvin WS; Ellison EC; Muscarella P
Pancreas; 2006 Oct; 33(3):246-9. PubMed ID: 17003645
[TBL] [Abstract][Full Text] [Related]
16. How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects?
Kim BJ; Lee KT; Moon TG; Kang P; Lee JK; Kim JJ; Rhee JC
Dig Liver Dis; 2009 May; 41(5):364-9. PubMed ID: 19162573
[TBL] [Abstract][Full Text] [Related]
17. False elevation of CA 19-9 levels in a patient with a history of pancreatic cancer.
Goetz M; Steen PD
Am J Gastroenterol; 1997 Aug; 92(8):1390-1. PubMed ID: 9260821
[TBL] [Abstract][Full Text] [Related]
18. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
19. Elevation of serum and urinary carbohydrate antigen 19-9 in benign hydronephrosis.
Aybek H; Aybek Z; Sinik Z; Demir S; Sancak B; Tuncay L
Int J Urol; 2006 Nov; 13(11):1380-4. PubMed ID: 17083387
[TBL] [Abstract][Full Text] [Related]
20. The clinical significance of elevated levels of serum CA 19-9.
Pavai S; Yap SF
Med J Malaysia; 2003 Dec; 58(5):667-72. PubMed ID: 15190651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
